Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: DavidCG who wrote (524)	10/18/1998 12:47:00 AM
From: PROLIFE	Read Replies (2) \| Respond to of 1255

Just my own observation FWIW> Take it however. I am involved currently in a drug study(NOT THIS ONE) with a major pharmaceutical co, actually a spin off of a major. Have been involved with the same drug for about 2 1/2 years and still looking at more tests for the next two years. What I have found out is that it is definitely LONG term to market. That may not matter so much when it comes to share price, but there it is anyway to think about. Unless it is some drug that the gov't wants in a hurry, not only will all the t's be crossed and i's dotted but the NIH will know if the guy crossing and dotting ever broke a nail doing it, sneezed on the pencil, or was married to a blue eyed tapdancer. Protocol is a very important to these folks. And this drug is just a different manufacturer of a same basic drug that has been on the market for a long time. I guess my question at this point would be aimed at those more familiar with Rx ,that can tell me how much market price depends on the drug in question actually getting to the public, and how long has this human drug study been going? Thanks, dan